Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yaroslav Ugolkov has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • SimuRg: Building, Fitting and Evaluating PK/PD Modeles

    by Victor Sokolov, Yaroslav Ugolkov, Anatoly Pokladyuk, Alina Melnikova, Victoria Kulesh

    Provides a unified workflow for building, fitting using external engines, and evaluating ordinary differential equation (ODE)-based pharmacokinetic/pharmacodynamic (PK/PD) models. Supports generation of estimation scenarios and control files for external engines (e.g., 'Monolix'), simulation of models using 'rxode2', and creation of goodness-of-fit diagnostics. Includes tools for covariate modeling, virtual population design, and local and global sensitivity analyses.

  • Open Access

    Quantitative systems pharmacology model of B cell immune response in mouse

    by Yaroslav Ugolkov, Alina Volkova, Gabriel Helmlinger, Kirill Peskov, Victor Sokolov

    B cell-mediated immunity plays a crucial role in long-term humoral protection. However, dysregulation of B cell development and differentiation may lead to the persistence of autoreactive clones, contributing to autoimmune diseases. Despite a number of therapeutic agents in preclinical and clinical development targeting B cell biology, several challenges still limit their successful translation into clinical use. To better understand B cell-targeting mechanisms of action quantitatively and mechanistically, we developed an integrative systems pharmacology model that describes T cell-dependent B cell response to antigen exposure in mouse. The model includes 20 ordinary differential equations representing key biological processes involved in the B lymphocyte response: B cell activation in secondary lymphoid organs; antibody-secreting cell (ASC) generation; migration to the bone marrow; and redistribution to peripheral tissues. The model adequately described ASC dynamics across tissues and IgG time profiles in plasma. Local and global sensitivity analyses identified the ASC production rate as the main contributor to cell counts in the spleen and in lymph nodes, while ASC levels in the bone marrow were primarily controlled by their influx rate, reflecting survival niche availability. Moderate variations of this influx rate parameter allowed the model to capture high inter-study variability in bone marrow ASC levels, explaining the observed heterogeneity in the functional immune response. The model can be further used as a quantitative tool to study B cell responses and their dysregulation in autoimmunity. It can be extended by integrating plasma-cell biology and autoantibody production, ultimately supporting the development of new therapeutic strategies for autoimmune diseases.

  • Open Access

    Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis

    by Marina Vaskeikina, Yaroslav Ugolkov, Boris Kireev, Kirill Peskov, Alina Volkova

    Background: Systemic sclerosis (SSc) is a complex autoimmune fibrotic disorder marked by heterogeneous clinical features and multiple pathophysiological mechanisms. The rapid emergence of targeted therapies, aimed at selectively modulating molecular targets, has expanded treatment options; however, making direct efficacy comparisons remains challenging due to the variability in trial designs, endpoints, and patient populations. Methods: A systematic search of PubMed and ClinicalTrials.gov identified randomized controlled trials (RCTs) evaluating targeted therapies in SSc. A longitudinal mixed-effect meta-model incorporating Emax structural functions characterized treatment response trajectories for the modified Rodnan skin score (mRSS) and forced vital capacity (FVC). Between-study and between-treatment-arm variability were explicitly modeled to account for heterogeneity. Results: A total of 32 RCTs with 2036 patients and 23 targeted agents were analyzed. Guselkumab, an anti-IL-23 antibody, showed the greatest effect on mRSS, followed by tofacitinib, inebilizumab, and baricitinib. For FVC, B-cell-targeted therapies, with belimumab and rituximab, demonstrated the highest efficacy, while tocilizumab and nintedanib had more moderate effects. Time to 50% maximal response was approximately 27.5 weeks, indicating a 6.3-month period for half treatment response development. Conclusions: This model-based meta-analysis provides a broad comparison of targeted therapies in SSc, highlighting distinct efficacy patterns for skin versus lung involvement and offering hypothesis-generating insights that may support treatment selection and the design of future clinical trials.


  • Open Access

    An Integrative Mechanistic Model of Type 1 IFN‐Mediated Inflammation in Systemic Lupus Erythematosus

    by Alina Volkova, Victor Sokolov, Florencia Tettamanti, Meghna Verma, Yaroslav Ugolkov, Kirill Peskov, Weifeng Tang, Holly Kimko

    Type I interferon (IFN1) pathway–targeting therapies represent a highly promising class of remedies for the treatment of systemic lupus erythematosus. However, the overall clinical benefit of these compounds is afflicted by marked variability. In this study, we developed a quantitative systems pharmacology model of type I IFN‐mediated inflammation and applied it for an indirect comparison of anifrolumab, sifalimumab, daxdilimab, and litifilimab pharmacodynamic response, represented in the model by the change in IFN1 gene signature (IFNGS). The model consists of 20 ordinary differential equations and 68 parameters, among which four systemic parameters (including one random effect) were estimated using patient‐level data from Phase IIb anifrolumab clinical trial. Within‐target and within‐pathway validation was performed using study‐level pharmacokinetics, IFNα, and/or IFNGS data from five anifrolumab, four sifalimumab, one daxdilimab, and one litifilimab trials. The model successfully captured overall trends in IFNGS at clinically relevant doses of these compounds and discriminated IFNGS response between patients with low (< 2.75) and high (≥ 2.75) baseline IFNGS. Overprediction of treatment benefit was observed for the low range of anifrolumab doses (100–150 mg every 4 weeks). In contrast, IFNGS response under 150 mg of daxdilimab was underpredicted, despite the accurate description of plasmacytoid dendritic cells and IFNα biomarkers. Results of the global sensitivity analysis revealed baseline IFNGS, IFNα, and IFNα fraction as key factors affecting treatment benefit the most. In terms of maximum IFNGS reduction, anifrolumab showed superior potential compared to sifalimumab, daxdilimab, and litifilimab (ΔIFNGS~25%), which was further enhanced in patients with high baseline IFNGS or IFNα (ΔIFNGS~50%–60%).


  • Open Access

    Mathematical modeling in autoimmune diseases: from theory to clinical application

    by Yaroslav Ugolkov, Antonina Nikitich, Cristina Leon, Gabriel Helmlinger, Kirill Peskov, Victor Sokolov, Alina Volkova

    The research & development (R&D) of novel therapeutic agents for the treatment of autoimmune diseases is challenged by highly complex pathogenesis and multiple etiologies of these conditions. The number of targeted therapies available on the market is limited, whereas the prevalence of autoimmune conditions in the global population continues to rise. Mathematical modeling of biological systems is an essential tool which may be applied in support of decision-making across R&D drug programs to improve the probability of success in the development of novel medicines. Over the past decades, multiple models of autoimmune diseases have been developed. Models differ in the spectra of quantitative data used in their development and mathematical methods, as well as in the level of “mechanistic granularity” chosen to describe the underlying biology. Yet, all models strive towards the same goal: to quantitatively describe various aspects of the immune response. The aim of this review was to conduct a systematic review and analysis of mathematical models of autoimmune diseases focused on the mechanistic description of the immune system, to consolidate existing quantitative knowledge on autoimmune processes, and to outline potential directions of interest for future model-based analyses. Following a systematic literature review, 38 models describing the onset, progression, and/or the effect of treatment in 13 systemic and organ-specific autoimmune conditions were identified, most models developed for inflammatory bowel disease, multiple sclerosis, and lupus (5 models each). ≥70% of the models were developed as nonlinear systems of ordinary differential equations, others – as partial differential equations, integro-differential equations, Boolean networks, or probabilistic models. Despite covering a relatively wide range of diseases, most models described the same components of the immune system, such as T-cell response, cytokine influence, or the involvement of macrophages in autoimmune processes. All models were thoroughly analyzed with an emphasis on assumptions, limitations, and their potential applications in the development of novel medicines.


  • Open Access

    Cellulose metabolism in halo(natrono)archaea: a comparative genomics study

    by Alexander G. Elcheninov, Yaroslav A. Ugolkov, Ivan M. Elizarov, Alexandra A. Klyukina, Ilya V. Kublanov, Dimitry Y. Sorokin

    Extremely halophilic archaea are one of the principal microbial community components in hypersaline environments. The majority of cultivated haloarchaea are aerobic heterotrophs using peptides or simple sugars as carbon and energy sources. At the same time, a number of novel metabolic capacities of these extremophiles were discovered recently among which is a capability of growing on insoluble polysaccharides such as cellulose and chitin. Still, polysaccharidolytic strains are in minority among cultivated haloarchaea and their capacities of hydrolyzing recalcitrant polysaccharides are hardly investigated. This includes the mechanisms and enzymes involved in cellulose degradation, which are well studied for bacterial species, while almost unexplored in archaea and haloarchaea in particular. To fill this gap, a comparative genomic analysis of 155 cultivated representatives of halo(natrono)archaea, including seven cellulotrophic strains belonging to the genera Natronobiforma, Natronolimnobius, Natrarchaeobius, Halosimplex, Halomicrobium and Halococcoides was performed. The analysis revealed a number of cellulases, encoded in the genomes of cellulotrophic strains but also in several haloarchaea, for which the capacity to grow on cellulose was not shown. Surprisingly, the cellulases genes, especially of GH5, GH9 and GH12 families, were significantly overrepresented in the cellulotrophic haloarchaea genomes in comparison with other cellulotrophic archaea and even cellulotrophic bacteria. Besides cellulases, the genes for GH10 and GH51 families were also abundant in the genomes of cellulotrophic haloarchaea. These results allowed to propose the genomic patterns, determining the capability of haloarchaea to grow on cellulose. The patterns helped to predict cellulotrophic capacity for several halo(natrono)archaea, and for three of them it was experimentally confirmed. Further genomic search revealed that glucose and cellooligosaccharides import occurred by means of porters and ABC (ATP-binding cassette) transporters. Intracellular glucose oxidation occurred through glycolysis or the semi-phosphorylative Entner-Dudoroff pathway which occurrence was strain-specific. Comparative analysis of CAZymes toolbox and available cultivation-based information allowed proposing two possible strategies used by haloarchaea capable of growing on cellulose: so-called specialists are more effective in degradation of cellulose while generalists are more flexible in nutrient spectra. Besides CAZymes profiles the groups differed in genome sizes, as well as in variability of mechanisms of import and central metabolism of sugars.